Drugs / Xenon
Trials 31
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06945614 | Apr → Dec 2025 overdue | — | General Biophysics LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT01043419 | Jan → Mar 2010 | sympathetic nervous system disorder | Air Liquide | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07435103 | Mar 2026 → Mar 2027 expected | autism | The Children's Hospital of Zhejiang University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT01545271 | May 2012 → Oct 2013 | brain hypoxia - ischemia | University Hospitals Bristol and Weston NHS Foundation Trust | Completed | No outcome recorded |
| Phase 28 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04696523 | Apr 2025 → Dec 2029 expected | acquired aneurysmal subarachnoid hemorrhage, brain injury, brain ischemia, cerebral infarction +1 | Turku University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT02768727 | Apr 2016 → Dec 2019 | cognitive disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT02071394 | Mar 2014 → Oct 2019 | brain hypoxia - ischemia | University Hospitals Bristol and Weston NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT02098148 | Nov 2013 → Jan 2014 | obsessive-compulsive disorder | Mclean Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01757106 | Dec 2012 → Jul 2013 | coronary artery disorder | Universitaire Ziekenhuizen KU Leuven | Completed | Met primary |
| Phase 2 | NCT01696630 | Oct 2012 → Jul 2014 | colorectal cancer | Centre Leon Berard | Completed | No outcome recorded |
| Phase 2 | NCT01262729 | Sep 2011 → Nov 2014 | cardiac arrest | RWTH Aachen University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01199276 | Sep 2010 → Oct 2014 | delirium | Air Liquide | Completed | Missed primary |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04432155 | Jun → Nov 2021 | panic disorder | Nobilis Therapeutics Inc. | Unknown | No outcome recorded |
| Phase 2/3 | NCT03635827 | Jun 2021 | post-traumatic stress disorder | Nobilis Therapeutics Inc. | Unknown | No outcome recorded |
| Phase 39 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT03176186 | Mar 2026 → Apr 2029 expected | post-cardiac arrest syndrome | Invero Pharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05335109 | Jan 2022 → Jan 2024 | ischemic stroke | Negovsky Reanimatology Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02129400 | May 2014 → Jan 2015 | — | RWTH Aachen University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01839084 | Jul 2013 → Feb 2016 | — | RWTH Aachen University | Completed | Missed primary |
| Phase 3 | NCT01285271 | May → Sep 2011 | coronary artery disorder | RWTH Aachen University | Completed | No outcome recorded |
| Phase 3 | NCT01294163 | Apr 2011 → Apr 2014 | coronary artery disorder, drug allergy | Air Liquide | Completed | No outcome recorded |
| Phase 3 | NCT01120405 | May 2010 → Jul 2012 | coronary artery disorder | Air Liquide | Completed | No outcome recorded |
| Phase 3 | NCT00919126 | Jun 2009 → Jan 2012 | — | Air Liquide SA | Terminated | Met primary Stop: Enrollment |
| Phase 3 | NCT00192959 | Mar → Dec 2004 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 45 trials · 1 missed | ||||||
| Phase 4 | NCT03504033 | Apr 2018 → Sep 2019 | — | RWTH Aachen University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02682758 | Feb → Mar 2016 | — | Heinrich-Heine University, Duesseldorf | Completed | Missed primary |
| Phase 4 | NCT01167803 | Dec 2010 → Nov 2012 | obesity disorder | Nîmes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00937807 | Jul 2009 → Feb 2010 | — | Air Liquide | Completed | No outcome recorded |
| Phase 4 | NCT00793663 | Nov 2008 → Apr 2011 | — | RWTH Aachen University | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT02774096 | Feb 2016 → Jul 2018 | aortic disorder | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| — | NCT02468531 | Jan 2015 → Jul 2017 | acute lung injury | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| — | NCT01404819 | Apr 2012 → Feb 2015 | — | Nîmes University Hospital | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT06080100 Comparator | Nov 2023 → Sep 2026 | anxiety | The S.N. Fyodorov Eye Microsurgery State Institution | Completed | No outcome recorded |
| Phase 0 | NCT03748446 Comparator | Dec 2019 → Nov 2025 | bipolar depression, major depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01948765 Comparator | Jun 2013 → Sep 2014 | coronary artery disorder | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 2 | NCT00879892 Comparator | May 2009 → Sep 2014 | brain ischemia | Turku University Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-25 | Invero Pharma, Inc. | Regulatory Invero Pharma Submits TBI IND for XENEX inveropharma.com ↗
Invero Pharma, through its affiliate Invero Health, LLC, a clinical-stage biopharmaceutical company developing neuroprotective therapies for acute brain injuries, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for XENEX®, its proprietary xenon gas-based therapy for severe traumatic brain injury (TBI). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-25 | Invero Pharma, Inc. | Invero Pharma Submits TBI IND for XENEX inveropharma.com ↗ |
| 2023-01-17 | Invero Pharma, Inc. | Invero Pharma Secures Exclusive Xenon Clinical Supply Agreement inveropharma.com ↗ |
| 2022-03-09 | Invero Pharma, Inc. | Invero Pharma Secures Exclusive Xenon Data Rights inveropharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xenon | “Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care” NCT04696523 ↗ |
| Known as | LENOXe | “Hemodynamic Stability During Carotid Endarterectomy.Comparison of LENOXe™ (Xenon 100% v/v) Versus Sevoflurane” NCT00937807 ↗1“Security under LENOXe™ (xénon 100 % v/v) anesthesia” NCT01043419 ↗ |
| Action | Inhibit | “In vitro, Xe decreases the uptake of NE in neuronal cells by the inhibition of NET.” PMID 22945969 ↗ Sep 2012 |
| Modality | Other / unclassified | “The N-methyl-d-aspartate (NMDA) receptor (NMDA-R) antagonist xenon (Xe) induces general anaesthesia” PMID 22945969 ↗ Sep 2012 |
| Route | Inhaled | “inhaled xenon” NCT00192959 ↗ |